Roche lung cancer therapy beats rivals from Amgen, BMS in late-stage trial

Summary

Roche's lung cancer therapy demonstrated superior efficacy compared to competing treatments from Amgen and BMS in a late-stage clinical trial. The positive Phase 3 data positions Roche competitively in the lung cancer treatment market.